3NC
GILD icon

300 North Capital’s Gilead Sciences GILD Stock Holding History

300 North Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-33,400
Closed -$2.1M – 112
2013
Q3 		$2.1M Buy
+33,400
New +$2M 0.49% 83

Other funds holding GILD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

300 North Capital's GILD Position: Q4 2013 in Review

300 North Capital sold out of Gilead Sciences (GILD) in Q4 2013, closing a stake of 33,400 shares — an estimated $2.1M sold.

300 North Capital first reported a position in GILD in Q3 2013 and held it in 1 quarter. The position peaked at $2.1M in Q3 2013. 1,099 funds tracked by Wall St. Rank hold GILD as of Q4 2013.

  • 300 North Capital reported no remaining Gilead Sciences position as of Q4 2013 after selling out during the quarter.
  • 300 North Capital sold 33,400 Gilead Sciences shares in Q4 2013, an estimated $2.1M.
  • 300 North Capital first reported a position in Gilead Sciences in Q3 2013 and held it in 1 quarter.
  • 300 North Capital's Gilead Sciences position peaked at $2.1M in Q3 2013.
  • 1,099 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2013.

Based on 300 North Capital's 13F filing for Q4 2013, filed 14 Feb 2014.